Buys | $9,600,000 | 1 | 1 |
Sells | $39,672,279 | 72 | 99 |
Graham G. Walmsley | director | 1 | $9.6M | 0 | $0 | $9.6M |
Lamy Patrick | Senior VP, Commercial Strategy | 0 | $0 | 5 | $403,733 | $-403,733 |
Rolph Timothy | Chief Scientific Officer | 0 | $0 | 8 | $3.72M | $-3.72M |
White William Richard | Chief Financial Officer | 0 | $0 | 10 | $6.66M | $-6.66M |
Young Jonathan | Chief Operating Officer | 0 | $0 | 17 | $7.35M | $-7.35M |
Yale Catriona | Chief Development Officer | 0 | $0 | 20 | $9.39M | $-9.39M |
Cheng Andrew | President and CEO | 0 | $0 | 12 | $12.14M | $-12.14M |
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH …
Over the last 12 months, insiders at Akero Therapeutics, Inc. have bought $9.6M and sold $39.67M worth of Akero Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Akero Therapeutics, Inc. have bought $25.57M and sold $36.63M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Graham G. Walmsley (director) — $9.6M.
The last purchase of 200,000 shares for transaction amount of $9.6M was made by Graham G. Walmsley (director) on 2025‑01‑30.
2025-03-12 | Sale | Cheng Andrew | President and CEO | 1,738 0.0021% | $44.88 | $78,001 | -2.93% | |
2025-03-12 | Sale | Young Jonathan | Chief Operating Officer | 607 0.0007% | $44.88 | $27,242 | -2.93% | |
2025-03-12 | Sale | Rolph Timothy | Chief Scientific Officer | 516 0.0006% | $44.88 | $23,158 | -2.93% | |
2025-03-12 | Sale | Yale Catriona | Chief Development Officer | 614 0.0008% | $44.88 | $27,556 | -2.93% | |
2025-03-12 | Sale | White William Richard | Chief Financial Officer | 676 0.0008% | $44.88 | $30,339 | -2.93% | |
2025-03-10 | Sale | Cheng Andrew | President and CEO | 30,000 0.0378% | $41.77 | $1.25M | +6.78% | |
2025-03-05 | Sale | Rolph Timothy | Chief Scientific Officer | 12,500 0.0154% | $44.53 | $556,590 | -2.95% | |
2025-03-04 | Sale | Young Jonathan | Chief Operating Officer | 50,000 0.0666% | $44.86 | $2.24M | -1.22% | |
2025-03-03 | Sale | Lamy Patrick | Senior VP, Commercial Strategy | 1,000 0.0014% | $48.09 | $48,090 | -3.05% | |
2025-02-18 | Sale | Yale Catriona | Chief Development Officer | 10,000 0.0131% | $49.87 | $498,660 | -9.00% | |
2025-02-10 | Sale | Cheng Andrew | President and CEO | 30,000 0.0388% | $52.73 | $1.58M | -8.03% | |
2025-02-05 | Sale | Rolph Timothy | Chief Scientific Officer | 18,750 0.025% | $56.51 | $1.06M | -15.60% | |
2025-02-03 | Sale | Young Jonathan | Chief Operating Officer | 10,000 0.0132% | $53.81 | $538,061 | -8.56% | |
2025-01-30 | Graham G. Walmsley | director | 200,000 0.2547% | $48.00 | $9.6M | -10.93% | ||
2025-01-27 | Sale | Cheng Andrew | President and CEO | 30,000 0.0459% | $54.90 | $1.65M | -4.28% | |
2025-01-27 | Sale | Rolph Timothy | Chief Scientific Officer | 31,250 0.0486% | $55.77 | $1.74M | -4.28% | |
2025-01-27 | Sale | Yale Catriona | Chief Development Officer | 102,664 0.1604% | $55.99 | $5.75M | -4.28% | |
2025-01-27 | Sale | Lamy Patrick | Senior VP, Commercial Strategy | 5,000 0.008% | $57.03 | $285,150 | -4.28% | |
2025-01-02 | Sale | Young Jonathan | Chief Operating Officer | 10,000 0.0144% | $28.03 | $280,330 | +66.17% | |
2024-12-17 | Sale | Rolph Timothy | Chief Scientific Officer | 3,800 0.0055% | $31.10 | $118,172 | +44.85% |
Graham G. Walmsley | director | 1000000 1.256% | $44.15M | 10 | 0 | +42.32% |
Apple Tree Partners IV, L.P. | 10 percent owner | 5830203 7.3225% | $257.4M | 2 | 0 | <0.0001% |
Versant Venture Capital VI, L.P. | 10 percent owner | 3092698 3.8843% | $136.54M | 1 | 22 | +13.18% |
venBio Global Strategic Fund II L.P. | 10 percent owner | 3033552 3.81% | $133.93M | 1 | 25 | +13.18% |
Atlas Venture Fund XI, L.P. | 10 percent owner | 505099 0.6344% | $22.3M | 1 | 0 | +13.18% |
$52,263,649 | 70 | 1.18% | $4.36B | |
$140,165,669 | 33 | 85.24% | $3.32B | |
$103,944,213 | 17 | 5.95% | $3.22B | |
$128,181,928 | 16 | 18.84% | $3.25B | |
$174,105,409 | 15 | 10.88% | $3.1B |
Increased Positions | 105 | +60.34% | 9M | +12.15% |
Decreased Positions | 69 | -39.66% | 7M | -9.03% |
New Positions | 38 | New | 3M | New |
Sold Out Positions | 20 | Sold Out | 368,386 | Sold Out |
Total Postitions | 210 | +20.69% | 75M | +3.13% |
Wellington Management Group Llp | $362,356.00 | 9.84% | 7.38M | -519,671 | -6.58% | 2024-12-31 |
Rtw Investments, Lp | $336,955.00 | 9.15% | 6.86M | +940,388 | +15.89% | 2024-12-31 |
Janus Henderson Group Plc | $296,402.00 | 8.05% | 6.03M | -1M | -14.74% | 2024-12-31 |
Blackrock, Inc. | $290,996.00 | 7.9% | 5.92M | +176,393 | +3.07% | 2024-12-31 |
General Atlantic, L.P. | $257,094.00 | 6.98% | 5.23M | 0 | 0% | 2024-12-31 |
Price T Rowe Associates Inc /Md/ | $212,295.00 | 5.76% | 4.32M | +513,613 | +13.49% | 2024-12-31 |
Vanguard Group Inc | $181,961.00 | 4.94% | 3.7M | +27,830 | +0.76% | 2024-12-31 |
State Street Corp | $114,742.00 | 3.12% | 2.34M | -167,002 | -6.67% | 2024-12-31 |
Alliancebernstein L.P. | $90,345.00 | 2.45% | 1.84M | -177,807 | -8.81% | 2024-12-31 |
Alkeon Capital Management Llc | $86,513.00 | 2.35% | 1.76M | -2M | -47.03% | 2024-12-31 |